Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 4Recruiting 3Active not recruiting 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 5004Neoplasms 4197Prostatic Neoplasms 2428Carcinoma, Non-Small-Cell Lung 2265Colorectal Neoplasms 2053Lung Neoplasms 1705Multiple Myeloma 1459Lymphoma 1405Leukemia, Myeloid, Acute 1382Neoplasm Metastasis 1374Melanoma 1270Pancreatic Neoplasms 1200Leukemia 1196Ovarian Neoplasms 1192Lymphoma, Non-Hodgkin 1132Precursor Cell Lymphoblastic Leukemia-Lymphoma 1091Head and Neck Neoplasms 1056Leukemia, Lymphocytic, Chronic, B-Cell 994Lymphoma, Follicular 897Colonic Neoplasms 895Brain Neoplasms 876Stomach Neoplasms 857Recurrence 853Carcinoma, Hepatocellular 846Glioblastoma 841Lymphoma, Large B-Cell, Diffuse 771Rectal Neoplasms 759Uterine Cervical Neoplasms 728Carcinoma, Renal Cell 705Hodgkin Disease 698

Interventions

seribantumab 2zenocutuzumab 1patritumab 1exemestane 1Vinorelbine 1Trastuzumab 1Letrozole 1Fulvestrant 1Erlotinib Hydrochloride 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Interventional × Lethal Congenital Contracture Syndrome 2 × Clear all
NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Merus B.V.

Phase 2 Completed
105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

NCT00734305 2016-09-01

Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

Merrimack Pharmaceuticals

Phase 1 Completed
44 enrolled 12 charts

Lethal Congenital Contracture Syndrome 2, Neoplasms

NCT00994123 2016-08-22

A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Merrimack Pharmaceuticals

Phase 1/2 Completed
162 enrolled 11 charts
Thoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00730470 2010-07-29

Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors

U3 Pharma GmbH

Phase 1 Completed
60 enrolled

Lethal Congenital Contracture Syndrome 2, Fibromatosis, Gingival, 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡